Composition for preventing, reducing and/or alleviating non-alcoholic steatohepatitis and its application

Abstract

The present invention proposes a composition for preventing, reducing and / or alleviating non-alcoholic steatohepatitis and its application, including β-glucan and pyrimidine derivatives. The combined use of the composition exhibits a synergistic effect in the treatment of nonalcoholic steatohepatitis.

Description

technical field [0001] The invention belongs to a composition for preventing, reducing and / or alleviating non-alcoholic steatohepatitis and its application. Background technique [0002] Nonalcoholic steatohepatitis (NASH) is a syndrome characterized by hepatic steatosis, ballooning, and diffuse hepatic lobular inflammation without excessive alcohol consumption. It belongs to Nonalcoholic fatty liver disease (NAFLD), a potentially fatal disease that can lead to cirrhosis and liver cancer. The exact pathogenesis of NASH has not been elucidated yet, but studies have shown that the pathogenesis of NASH is closely related to insulin resistance, obesity, hyperlipidemia and metabolic syndrome. With the increase in the incidence of such diseases, the prevalence of NASH is gradually increasing. At present, most of the treatment methods in clinical trials are ineffective. There is no evidence-based medical evidence for the drug treatment of NASH. Therefore, it is of great signifi...

AI Technical Summary

Problems solved by technology

So far, the synergistic effect of this pyrimidine derivative and β-glucan on the prevention and treatment of non-alcoholic fatty liver has not been reported

Images